Elecsys Anti-HBc IgM
Roche Diagnostics · Decision date Apr 7, 2026
What did the FDA decide?
FDA records K260049 as a 510(k) premarket notification, with a decision dated Apr 7, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Apr 7, 2026
Regulatory record facts
- Identifier
- K260049
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Roche Diagnostics
- Product code
- SEI
- Decision code
- SESE
- Decision date
- Apr 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Qualitative And Quantitative Hepatitis B Virus Antibody Assays.
- Applicant
- Roche Diagnostics
- Product code
- SEI
- FDA device class
- 2
FDA decision timeline
K260049 received
Application receipt date recorded by FDA.
K260049 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code SEI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Elecsys Anti-HBc IIK260046 | Roche Diagnostics | 510(k) clearance | Apr 7, 2026 | FDA |
Access anti-HBc IgMK254059 | BECKMAN COULTER, INC. | 510(k) clearance | Mar 13, 2026 | FDA |
Access anti-HBc TotalK253687 | BECKMAN COULTER, INC. | 510(k) clearance | Feb 19, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Diagnostics
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Indianapolis, IN
Sources and methodology
- Original FDA record: K260049
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

